



## Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

April 28, 2025

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Apr. 28, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA.

Details of the oral presentation are as follows:

**Title:** ADI-270, an Armored Allogeneic Anti-CD70 CAR  $\gamma\delta$  T Cell Therapy, Demonstrates Robust CAR-Directed and -Independent Anti-Tumor Activity Against Hematologic and Solid Tumor Models Compared to Conventional CAR  $\alpha\beta$  T Cells

**Session Name:** Engineered Immune Effector Cells for Solid Tumors

**Presenting Author:** Melinda Au

**Date and Time:** May 17, 2025; 11:45 a.m. – 12:00 p.m. CT

### About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250428536799/en/): <https://www.businesswire.com/news/home/20250428536799/en/>

### Adicet Bio, Inc.

#### Investor and Media Contacts

##### Investors:

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Precision AQ

212-362-1200

[janhavi.mohite@precisionaq.com](mailto:janhavi.mohite@precisionaq.com)

##### Media:

Kerry Beth Daly

[kbdaly@adicetbio.com](mailto:kbdaly@adicetbio.com)

Source: Adicet Bio, Inc.